glp 1 drugs wegovy GLP-1 weight loss may be misused by patients with eating disorders: Study With FDA approval of Wegovy
Description
(HKEX: 1672) has unveiled ASC35, a next-generation GLP-1/GIP dual peptide agonist designed for once-monthly subcutaneous dosing in obesity treatment.
Analysis of nearly 8,000 adults found 45% keep the weight off after one year
There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.
Find out how to verify it's FDA-approved and avoid compounded knockoffs that could put your health at risk.
